PPARG and cardiac hypertrophy: Although the therapeutic outcomes of transgenic mice and rosiglitazone are ambiguous (25, 32), there is increasing evidence that PPARγ is a protective modulator in cardiac hypertrophy (26–28, 33) and heart failure (31, 34).